Salazar O M, Rubin P, McDonald J V, Feldstein M L
AJR Am J Roentgenol. 1976 Feb;126(2):279-92. doi: 10.2214/ajr.126.2.279.
The choice of tumor dose and treatment volume are the two most important radiation factors influencing survival in glioblastomas. Patients treated to their whole brain survive longer than those treated with limited fields. Glioblastomas treated with over 5,000 rads (1,300 rets) survive longer than those treated with smaller doses. Other factors affecting survival are: the pathological grade; age at diagnosis; and surgical treatment performed. Failure patterns in glioblastomas represent intrinsic qualities of the tumor, the host, and the treatment employed. They dictate the strategy to follow. Perhaps some of these are unaffected by irradiation. An increase in dose and the extension of fields in glioblastomas have produced a gain in both the quantity and the quality of survival. The whole brain is treated (5,000-6,000 rads) and the target volume is boosted to 7,000 to 8,000 rads. Grade II astrocytomas perhaps should be treated with whole brain irradiation (4,500 rads) and a boost to the target volume of an additional 1,000 rads.
肿瘤剂量和治疗体积的选择是影响胶质母细胞瘤患者生存的两个最重要的放疗因素。全脑放疗的患者比局部野放疗的患者生存期更长。接受超过5000拉德(1300雷姆)放疗的胶质母细胞瘤患者比接受较小剂量放疗的患者生存期更长。影响生存的其他因素包括:病理分级;诊断时的年龄;以及所实施的手术治疗。胶质母细胞瘤的失败模式代表了肿瘤、宿主及所采用治疗的内在特性。它们决定了后续的治疗策略。也许其中一些不受放疗影响。增加胶质母细胞瘤的剂量和扩大照射野已使生存的数量和质量均有所提高。全脑接受放疗(5000 - 6000拉德),靶区体积追加放疗至7000 - 8000拉德。二级星形细胞瘤或许应采用全脑照射(4500拉德),并对靶区体积追加1000拉德的放疗剂量。